Ann: Positive preclinical data for deoxymabs in vasculitis, page-51

I see your points and I disagree: Dr Campbell hi had 10 years to develop the assets and bring them to the clinic and that - and nothing else - would create value for the shareholders ( his job ). He had plenty time to bring DX1 - at least- to human trials or demonstrate that GMP grade for trials can be successfully and repeatedly produced so that perhaps a licensing deal could come forward. Dr Campbell doesn’t even know what the actual problem is with the GMP ‘s run and ‘believes’ that it is a sporadic issue.
Accordingly, Dr Campbell hasn’t done his job properly and now the market will settle for nothing less than a successful run with NO issues attached.
Lastly: judging from the sp it would seem that the selling for tax purposes has been going on for the last six months at least: look at the chart.